MICROVUETMPTH ELISA (High Sensitive)

Over the years, studies involving the intermittent dosing of human PTH (1-34) in animals and humans have demonstrated an anabolic effect on bone. This effect was positive for bone mass, size, structure, and strength, demonstrating the antifracture efficacy of the treatment. The FDA has approved the recombinant form of human PTH (1-34) – rhPTH (1-34) or teriparatide, for treatment of many forms of osteoporosis. The measurement of circulating levels of this peptide/drug may be useful in assessing its pharmacological properties and for appropriate dosing and schedule optimization. Additionally, this assay may be useful in screening samples for both endogenous levels of circulating hPTH (1-34) and elevated levels of this peptide as it may interfere to varying degrees with 2-site immunometric assays used for measuring intact PTH (1-84) .